Fulgent Genetics, Inc. (FLGT) Tops Q2 EPS by 25c

Fulgent Genetics, Inc. (NASDAQ: FLGT) reported Q2 EPS of ($0.08), $0.25 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $68 million versus the consensus estimate of $62.48 million.

For earnings history and earnings-related data on Fulgent Genetics, Inc. (FLGT) click here.

You May Also Be Interested In

• UBS sees a negative catalyst ahead for Nike: Here’s what to watch
• Surgery Partners sells Idaho Falls facilities to Intermountain Health for $797M
• Trio-Tech wins $4.7M automotive semiconductor burn-in contract